Bank of America's analyst Michael Ryskin has boosted the price target for Quest Diagnostics (DGX, Financial) from $190 to $198, while maintaining a Buy rating on the stock. Despite the heightened negativity surrounding the Life Sciences and Diagnostic Tools sector as well as Contract Research Organizations, Ryskin remains optimistic about Quest Diagnostics' prospects.
This sector faces challenges due to several policy changes stemming from the Trump Administration, including reductions in the National Institutes of Health (NIH) budget, international tariffs, and macroeconomic uncertainties, particularly those associated with China. Ryskin's analysis suggests that these factors are creating a clouded outlook as companies within this field prepare to report their earnings.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 16 analysts, the average target price for Quest Diagnostics Inc (DGX, Financial) is $180.28 with a high estimate of $195.00 and a low estimate of $160.00. The average target implies an upside of 8.63% from the current price of $165.96. More detailed estimate data can be found on the Quest Diagnostics Inc (DGX) Forecast page.
Based on the consensus recommendation from 20 brokerage firms, Quest Diagnostics Inc's (DGX, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Quest Diagnostics Inc (DGX, Financial) in one year is $156.79, suggesting a downside of 5.53% from the current price of $165.96. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Quest Diagnostics Inc (DGX) Summary page.
